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Abstract 
Objective 
Literature concerning the impact of Multiple Endocrine Neoplasia Type 1 (MEN 1) on fertility is 
limited to case reports despite the early onset of endocrinopathies, such as primary 
hyperparathyroidism and prolactinoma, that may impact fertility. This study describes the impact of 
unrecognised and untreated MEN 1 on fertility and pregnancy outcomes in a multigenerational 
cohort of the Tasman 1 MEN 1 kindred. 
 
Methods 
All MEN 1 positive (MEN 1+, n=63) and MEN 1 negative (MEN 1-, n=75) descendants born between 
1825 and 1951 of a common founder. Review of birth, death, marriage and medical records 
provided data on date of birth and death, gender, MEN 1 status and the number of pregnancies and 
children per parent.  
 
Results 
Compared to MEN 1- parents, MEN 1+ parents had more children (RR 1.30, 1.02-1.66) and live births 
(RR 1.31, 1.02-1.67) with no excess of stillbirths (RR 1.24, 0.24-6.36). Compared to the era-matched 
Tasmanian fertility rate, MEN 1+ parents had more children (4.87±4.11 vs 3.40±0.61, p=0.048), 
whereas MEN 1- parents had similar numbers of children (3.67±3.27 vs 3.36±0.62, p=0.55). MEN 1+ 
parents had a similar number of MEN 1+ and MEN 1- offspring (2.1±1.9 vs 2.5±2.3, p=0.31). Indirectly 
assessed miscarriage rate was similar between MEN 1+ and MEN 1- mothers (p=0.77). Clinically overt 
pituitary disease reduced MEN 1+ kindred member likelihood of parenthood (33% vs 97%).  
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Conclusions 
There was no adverse impact of MEN 1 on patient fertility overall, however MEN 1-related pathology 
may have impaired the reproductive potential of a subset of individuals with pituitary disease.  
 
Introduction 
Multiple endocrine neoplasia type 1 (MEN 1) is a highly penetrant, autosomal dominant hereditary 
neoplasia syndrome caused by loss of function mutation in the MEN 1 gene.1-3 MEN 1 predisposes 
carriers to multi-system neoplasia including early-onset primary hyperparathyroidism, 
gastroenteropancreatic tumours, pituitary adenomas, particularly prolactinomas, adrenal, bronchial 
and thymic malignancy.4-6 Primary hyperparathyroidism occurs in up to 75% of MEN 1 carriers before 
21 years of age, requiring operative intervention in approximately one third.7 Pituitary adenomas 
occur in up to one third of MEN 1 carriers before 21 years of age, with three quarters of affected 
patients women and 70% prolactinomas.6, 7 Prolactinoma may reduce fertility8, 9 and primary 
hyperparathyroidism is potentially associated with maternal and neonatal complications.10, 11 
Aggressive MEN 1-associated neoplasms may also occur at any age.7  
 
Despite the early onset of MEN 1-associated manifestations that may impact reproductive health, 
data concerning the impact of MEN 1 on pregnancy and fertility is limited to isolated case reports 
and inference from experience with more common sporadic single organ dysfunction, such as 
isolated primary hyperparathyroidism.12, 13 Directly translating experience from sporadic single organ 
dysfunction to patients with MEN 1 may not be appropriate as the pathophysiology, natural history 
and sequelae of MEN 1-related primary hyperparathyroidism and prolactinoma differs compared to 
sporadic counterparts.6, 14-16 Existing case reports of MEN 1-associated pregnancies highlight 
challenging cases of MEN 1 during pregnancy,12, 13 however these may be biased toward a complex 
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subset of MEN 1 patients. A comprehensive perspective on the impact of MEN 1 status on fertility is 
lacking. 
 
Tasmania is an island state in Australia established as a European colony in the early 1800s with a 
small founding population, strong emphasis on record keeping and limited population migration. The 
early immigrant population of Tasmania included a founder carrying a pathogenic MEN 1 genotype, 
the descendants of whom define the Tasman 1 MEN 1 kindred.17,18 This pedigree spans from the 
1825-present day and includes over 2500 individuals across nine generations. The MEN 1 population 
in Tasmania was first characterised in the mid-1980s, however the detailed record keeping in 
colonial Tasmania allowed tracing of the pedigree to the founding ancestors. Subsequent cross-
referencing with historical birth, death, marriages and medical records provides the opportunity to 
understand the natural history and intrinsic impact of MEN 1 on fertility in a multigenerational MEN 
1 cohort prior to the recognition of MEN 1 in Tasmania.  
 
To determine the natural history of unrecognised MEN 1 on fertility and pregnancy outcomes we 
examined the effect of (1) parental MEN 1 status overall and (2) maternal and paternal MEN 1 status 
on reproductive outcomes. 
 
Materials and methods  
The Tasman 1 MEN 1 kindred contains over 2500 descendants of a common ancestor known to have 
carried a MEN 1 NM_130799.2:c446-3, C.G gene mutation. Research undertaken since the 1980s has 
established the kindred pedigree by interrogating and cross referencing multiple historical records 
including births, deaths and marriages registries, medical and archival records and family surveys. All 
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contactable members of Tasman 1 MEN 1 kindred were invited to participate in a prospective MEN 1 
screening program as previously described.17,18 The medical records of those individuals dying before 
the commencement of prospective family screening were reviewed where available. The diagnosis 
of MEN 1 was based on 1) development of characteristic endocrine disease; 2) the presence of the 
Tasman 1 MEN 1 gene mutation on genetic testing; or 3) a position in the pedigree mandating 
inheritance of the Tasman 1 MEN 1 mutation. Kindred members who died prior to the availability of 
genetic testing were only designated as MEN 1 positive (MEN 1+) identified as obligate mutation 
carriers or if they developed of characteristic endocrinopathy that rendered the diagnosis highly 
probable on phenotypic criteria.17,18 Data included date of birth (DOB), date of death, gender and 
MEN 1 status for parents and children. For parents, the number of pregnancies and children were 
also recorded. The research program was approved by the Human Research Ethics Committee of the 
University of Tasmania. 
 
To establish the natural history and impact of MEN 1 on fertility only parents who completed their 
reproductive lifespan before the MEN 1 characterisation period in Tasmania were included. As the 
Tasman 1 MEN 1 kindred was first characterised in the mid-1980s with case identification extending 
into the 1990s, all descendents included in the present analysis were born prior to 1951. Thus the 
youngest descendent included in present analysis would have been 40 years of age by the time the 
Tasman 1 MEN 1 kindred was well defined in 1990.  
 
To establish the impact of MEN 1 status on fertility all MEN 1 positive (MEN 1+) descendents were 
compared against all MEN 1 negative (MEN 1-) siblings within the Tasman 1 kindred. Data on 
miscarriage were not reliably available. Therefore, to indirectly assess the potential impact of MEN 1 
status on miscarriage frequency, children were stratified by parental age at birth and the 
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proportions of children in each parent age category (<20, 20-25, 25-30, 30-35 and >35 years) 
compared. The hypothesis tested was that, if MEN 1 was associated with a significant increase in 
miscarriage rate, then on average births would be more likely to occur later in the reproductive 
lifespan. This would manifest as a higher proportion of births later in life to MEN 1 positive parents, 
particularly mothers.  
 
To establish the impact of era of birth on fertility, MEN 1+ and MEN 1- cohorts separated by median 
year of birth with the original Tasman 1 founder excluded as there was no contemporary MEN 1- 
siblings. To assess the generalisability of findings beyond the Tasman 1 kindred the number of 
children born to MEN 1+ and MEN 1- parents within the kindred were compared with the average 
Tasmanian fertility rate adjusted by parental era of birth. Tasmanian total fertility rate was used to 
estimate the era-matched average Tasmanian fertility rate for all parents except those  prior to 1886 
where total fertility rates for Tasmania were unavailable and cohort fertility (children ever born) was 
used.19-23 To establish the impact of ‘parent of origin’ (i.e. the parent who was MEN 1+) on pregnancy 
outcomes all MEN 1+ men were compared against all MEN 1+ women.  
 
Where data were not available for parent of origin MEN 1 status (n=1, 0.7%), child gender (n=9, 
1.7%) or MEN 1 status (n=8, 1.5%), these data were excluded from the relevant analysis. Where 
disease or death likely impacted on the reproductive lifespan (defined as age 16-44 years; n=15, 
10.8%), these data were included in initial analyses. As MEN 1 phenotype manifests in an age-
dependent manner, for offspring MEN 1 status to be defined as positive or negative, the offspring 
had to live to at least 20 years of age or manifest clear MEN 1-related pathology prior to 20 years of 
age. Offspring who died prior to 20 years of age were classified as unknown MEN 1 status unless 
they had already developed unequivocal MEN 1-related pathology (n=1, 0.2%) prior to death. 
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Univariate analysis utilised t-tests and χ2 tests to compare differences in means and proportions, 
respectively. Multivariable analysis utilised Log-Poisson regression analyses were used to investigate 
the relationship between parental MEN 1 status and number of births, live births, stillborn children, 
male and female children, paternal and maternal births. Negative binomial models were used to 
correct for over-dispersion where the assumptions of the Log-Poisson models were not satisfied. 
Data were transformed when not normally distributed. Statistical significance was defined as a two 
tailed p value ≤0.05. Data were collated and statistical analysis performed using GRAPHPAD PRISM 
(GRAPHPAD Software Inc. La Jolla, CA, USA) and R (The R Foundation, Vienna, Austria).  
 
Results 
Between 1825 and 1950 the Tasman 1 kindred comprised six generations and 137 descendants of a 
common ancestor. There were no births recorded after 1985 for members of the Tasman 1 kindred 
who were born prior to 1951.  
 
Univariate analysis 
Table 1 summarises cohort characteristics and fertility outcomes stratified by parental MEN1 status. 
63 MEN 1+ and 75 MEN 1- parents were included in the analysis, providing a 87% power to detect a 
50% reduction in the number of pregnancies to MEN 1 parents taking the observed average number 
of births in the MEN 1- cohort and standard deviations in both groups. MEN 1+ and MEN 1- parents 
were comparable with regard to median year of birth (1929 vs 1929, p=0.93) and gender balance 
(42.8 vs 56 % male, p=0.12). MEN 1+ parents had more daughters (2.5±2.3 vs 1.7±1.8, p=0.02), but 
there was no significant difference between MEN 1+ and MEN 1- parents with regard to the average 
number of children (4.9±4.1 vs 3.7±3.3, p=0.06), number of sons (2.3±2.3 vs 2.0±1.9, p=0.37) or 
proportion of stillborn children (1% vs 1.1%, p=0.75) in univariate analysis (Table 1).  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
There was no significant difference in the average number of children between MEN 1+ and MEN 1- 
parent when stratified by median year (1929) of parent birth (Table 1). The proportion of children 
stratified by parental age at birth was similar between MEN 1+ and MEN 1- parents as a whole (Table 
1) and when only MEN 1+ and MEN 1- mothers (χ2 1.8, p=0.77) or fathers (χ2 2.1, p=0.71) were 
considered. There was no significant difference between MEN 1+ and MEN 1- parents as a whole 
(23.4±4.6 vs 23.4±4.0 years, p=0.88) or MEN 1+ and MEN 1- mothers (21.6±3.3 vs 22.2±4.1 years, 
p=0.56) in the age at which they had their first child.   
 
The proportion of descendents who reached reproductive age, but had events or pathology that 
interfered with reproductive lifespan (defined as 16-44 years of age) was similar between MEN 1+ 
and MEN 1- kindred members (Table 1). The impact of interference with reproductive lifespan on 
number of births was similar between MEN 1+ and MEN 1- kindred members (pinteraction=0.97). MEN 1
- 
kindred members were more likely to have infectious disease, ischemic heart disease or accidental 
death as the cause for interference with their reproductive lifespan than MEN 1+ kindred members 
(100% vs 11.1% of interference with reproductive lifespan, Table 2). There was a trend towards 
greater overall risk of death from accidental, infectious or cardiovascular aetiologies between 20 to 
40 years of age in MEN 1- compared to MEN 1+ kindred members (5 of 75 MEN 1-  vs 0 of 63 MEN 1+ 
kindred members). Two of three MEN 1+ kindred members who reached reproductive age but had 
clinically overt pituitary disease  did not have children compared to two of sixty MEN 1+ kindred 
members who did not have clinically overt pituitary disease. The MEN 1+ kindred member with 
clinically overt pituitary disease who had children first had their pituitary pathology become clinically 
overt after 55 years of age. A further MEN 1+ kindred member died prior to reproductive age due to 
haemorrhage into a pituitary neoplasm.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Multivariable analysis 
Table 3 summarises multivariate fertility outcomes of MEN 1+ kindred members referenced against 
MEN 1- kindred members. Compared to MEN 1- parents, MEN 1+ parents, particularly fathers, had a 
greater total number of children, live births and daughters parents in multivariable analysis. There 
was no difference between MEN 1+ and MEN 1- parents with regard to the number of sons, maternal 
births or stillborn children (Table 3). After controlling for the total number of births, there was no 
significant deficit in the number of sons (RR 0.86, 0.67-1.10) or excess in the number of daughters 
(RR 1.12, 0.86-1.45) born to MEN 1+ parents compared to MEN 1- parents.  
 
To assess the external validity of these results, we compared MEN 1+ and MEN 1- kindred members 
to the era-matched average Tasmanian fertility rate. There was no significant difference in the 
average number of children born to MEN 1- parents compared to the era-matched Tasmanian 
fertility rate (3.67±3.27 vs 3.36±0.62, p=0.55). MEN 1+ parents had significantly more children 
compared to the era-matched Tasmanian fertility rate (4.87±4.11 vs 3.40±0.61, p=0.048). This was 
primarily driven by MEN 1+ fathers (5.30±4.67 vs 3.30±0.54, p=0.04) rather than MEN 1+ mothers 
(4.37±3.54 vs 3.42±0.48, p=0.40). Exclusion Tasman 1 kindred members whose reproductive lifespan 
was interrupted due to either premature death or significant pathology did not meaningfully alter 
the results of comparison between MEN 1+ or MEN 1- parents and the Tasmanian fertility rate. 
 
Table 4 summarises MEN 1+ cohort characteristics and fertility outcomes stratified by parent gender. 
There was no significant difference between MEN 1+ mothers and fathers with regard to parental 
year of birth, total number of births, sons or daughters, live births or stillbirths (Table 4). There was 
no significant difference in the average number of children per MEN 1+ mother compared to MEN 1+ 
father for parents who were born either before or after the median birth year (1929) for MEN 1+ 
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parents. The proportion of offspring after stratification for parental age was significantly different 
between MEN 1+ mothers and fathers (p<0.001), with mothers having more children before 20 years 
of age (p=0.01) and fathers having more children after 35 years of age (p=0.04). Multivariable 
analysis adjusting for parental date of birth and interference with reproductive lifespan did not 
meaningfully change the results of univariate analysis (data not shown). There was no significant 
differences in the number of MEN 1+ offspring compared to MEN 1- offspring from MEN 1+ parents 
(2.1±1.9 vs 2.5±2.3, p=0.31) or the theoretical frequency of positive offspring for an autosomal 
dominant condition (p=0.23). The proportion of MEN 1+ and MEN 1- children did not differ 
significantly with parental MEN 1 status (p=0.75).  
 
Discussion 
In this historical population-based analysis of the Tasman 1 MEN 1 kindred spanning six generations 
from 1825-1990 there was no adverse impact of MEN 1 on fertility, stillbirth rate or apparent 
miscarriage rate. Thus, despite encompassing a 165 year historical period during which MEN 1 was 
not recognised or treated and medical care only rudimentary during earlier generations, the 
reproductive success of MEN 1 carriers was at least equivalent to sibling and population controls. 
While some instances of MEN 1-related pathology directly impairing reproductive potential were 
evident within the Tasman 1 kindred, MEN 1 positivity did not appear to detrimentally impact 
fertility or in utero viability of the neonate for the majority of MEN 1 carriers. Thus our data 
complement existing case reports, 12, 13 suggesting that for a subset of MEN 1+ patients with high risk 
phenotypes, targeted intervention may be required. However, for the majority of MEN 1-related 
pregnancies, judicious investigation and a tendency towards careful antenatal observation may be a 
reasonable approach. 
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Strengths of this analysis include review of six generations spanning 165 years, strict case criteria to 
define MEN 1+ status, restriction of the analysis to an era prior to MEN 1 being recognised in 
Tasmania and availability of MEN 1- sibling and contemporary population data to act as controls. To 
be designated as MEN 1+, Tasman 1 kindred members had to manifest characteristic pathology, have 
a positive genetic test or occupy a position in the pedigree mandating inheritance of the MEN 1 gene 
mutation. While all births for Tasman 1 kindred members born prior to 1951 were considered, there 
were no births to parents in this cohort after 1985. Thus all births considered in the present analysis 
occurred prior to 1985, a period when MEN 1 was unrecognised in Tasmania. The use of MEN 1- 
siblings as controls allowed tight matching of socioeconomic, geographic, lifestyle, era and non-MEN 
1 genetic factors that may impact fertility. To confirm the external validity of this approach we used 
the era-matched fertility rate of the general Tasmanian population derived from census data. This 
demonstrated no difference between MEN 1- members of the Tasman 1 kindred and the broader 
Tasmanian population and produced similar findings whether MEN 1+ parents were compared to 
their MEN 1- siblings or the era-matched population average. These findings support the 
generalisability of our findings and suggest that any potential misclassification of historical Tasman 1 
kindred members with subclinical MEN 1 as MEN 1- did not meaningful impact results.   
 
The total number of births and live births was greater for MEN 1+ parents compared to MEN 1- 
siblings in multivariable analysis and population controls. It is theoretically conceivable that 
heterozygote loss of function of the MEN 1 gene, as a bifunctional regulator of cell proliferation, may 
confer a reproductive advantage.24, 25 However, the difference in births was attributable to paternal 
offspring and there was no increase in MEN 1+ children. Based on these data it seems implausible 
that MEN 1 positivity confers a biological reproductive advantage. The most likely explanation for 
this finding is survivor bias whereby for the Tasman 1 kindred to be recognised as a large MEN 1 
pedigree, reproductive success, potentially in excess of the general population, in the preceding 
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generations was likely. Overall our data support the concept that MEN 1 does not adversely impact 
fertility for the majority of carriers, but that it is also unlikely to confer a biological reproductive 
advantage.   
 
The equivalent fertility between MEN 1+ and MEN 1- members of the Tasman 1 kindred suggests that 
the impact of MEN 1-related manifestations on fertility is not significant on a population basis. 
Primary hyperparathyroidism and pituitary adenomas, particularly prolactinomas, commonly occur 
before 20 years of age in MEN 1, though the majority are asymptomatic.7 Primary 
hyperparathyroidism has traditionally been associated with a high frequency of maternal and 
neonatal adverse outcomes in case reports and series.10, 11 However, more recent population based 
analyses suggest that the majority of patients with primary hyperparathyroidism can progress 
through pregnancy uneventfully and that the frequency of adverse outcomes appears to relate to 
the degree of hypercalcemia, rather than its presence or absence.10, 26, 27 Our data support this 
perspective, as it is likely that the majority of maternal MEN 1 pregnancies would have occurred in 
the context of unrecognised primary hyperparathyroidism. However, examples of premature death 
secondary to complications of hypercalcemia within the kindred underline the need for judicious 
intervention.  
 
Clinically overt pituitary neoplasms appeared to decrease the reproductive success of individual 
members in the Tasman 1 kindred, but subclinical pituitary disease, which is likely to have been 
present in a further 15-20%,7 was not sufficient to impact on the fertility of the cohort as a whole. 
These data are similar to a limited analysis of a Finnish MEN 1 kindred, which lacked a comparator 
group, however described close to 100% reproductive fitness of MEN 1+ members of the kindred.28 
Overall our data suggest that for the majority of MEN 1-associated pregnancies, judicious 
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investigation and a tendency towards careful antenatal observation may be a reasonable approach, 
but that for selected patients, targeted intervention may be required.  
 
Directly assessed miscarriage rate was below the resolution of this historical cohort. To indirectly 
assess miscarriage rate, the proportion of births stratified by the parental age at which they 
occurred was compared. There was no significant difference in the proportion of births at each age 
category between MEN 1+ and MEN 1- parents as a whole or when stratified by parental gender. This 
could be explained by (1) no significant increase in miscarriages associated with MEN 1 or (2) an 
increase in miscarriage rate in MEN 1 positive parents that is compensated for by an earlier entry 
into reproductive lifespan or higher fertility. Based on these results, researchers should expect to 
find either (1) no excess of miscarriages related to MEN 1, (2) an excess of miscarriages related to 
high risk phenotypes only that do not impact cohort fertility overall, or (3) or an excess of 
miscarriages that is balanced by greater number of total pregnancies. The absence of a significance 
difference in age at which MEN 1 positive parents had their first child suggests the third possibility is 
less likely. 
 
There was no adverse impact of maternal MEN 1+ status on reproductive success, offspring gender 
or offspring MEN 1+ frequency. While MEN 1+ mothers had children and completed their families 
earlier than MEN 1+ fathers, there was no significant difference in the timing of children born to 
MEN 1+ and MEN 1- mothers or MEN 1+ and MEN 1- fathers, suggesting that non-MEN 1 factors were 
responsible. More daughters were born to MEN 1+ parents, however this likely reflects the greater 
total number of births as adjustment for the total number of births in multivariable analysis 
rendered this result non significant. Importantly, there was no significant deficit in MEN 1+ offspring 
compared to MEN 1- offspring or to the theoretical frequency of positive offspring for an autosomal 
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dominant condition and proportion of MEN 1+ and MEN 1- children did not differ significantly with 
the parental MEN 1 status. This suggests that there is no disadvantage to neonatal MEN 1 in utero 
and that there is no major interaction between maternal and fetal MEN 1 status that detrimentally 
impacts survival to adulthood. 
 
Misclassification of exposure or outcome is a common source of bias in population studies. Outcome 
measures (births and deaths) used herein were derived from historical databases, minimising the 
potential for outcome misclassification. Attributing MEN 1+ status to MEN 1 phenocopy and MEN 1- 
status to undiagnosed subclinical MEN 1 both represent potential sources of bias secondary to 
misclassification of exposure in our analysis. Modern generations of the Tasman 1 MEN 1 kindred 
have had their MEN 1 status confirmed genetically, minimising the possibility of misclassification, 
however this was not possible for earlier deceased generations. MEN 1 phenocopy may account for 
up to 10% of cases of familial MEN 1 when sensitive diagnostic criteria such as isolated mild 
biochemical primary hyperparathyroidism or pituitary microadenoma together with family history 
are used.29 However, misclassification of MEN 1 phenocopy as MEN 1+ status is likely to be far less in 
the present analysis as earlier generations of were classified as MEN 1+ only when unequivocal 
clinically overt MEN 1-related pathology manifested or if they were obligate carriers of the MEN 1 
gene mutation.  
 
Strict case definition criteria may underestimate the prevalence of MEN 1+ individuals. As MEN 1 
phenotype manifests in an age-dependent, our criteria for MEN 1+ status were particularly likely to 
result in misclassification if premature death from non MEN 1-related aetiologies intervenes. This is 
reflected greater interference with reproductive lifespan and a trend towards an apparent excess of 
early adulthood death from ischemic heart disease, infectious and accidental aetiologies in those 
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designated MEN 1- compared to MEN 1+ kindred members in our cohort. Therefore the major source 
of misclassification error in our analysis is likely to be attributing MEN 1- status to subclinical MEN 1. 
To account for this we compared MEN 1+ parents with non-sibling population averages. This yielded 
similar results to comparison with MEN 1- sibling controls, suggesting potential misclassification of 
siblings with undiagnosed subclinical MEN 1 as MEN 1- did not meaningfully impact results overall.  
 
This analysis comprises a single large pedigree with a common MEN 1 gene mutation, which may 
theoretically limit generalisability. However, to date there has been no reproducible genotype-
phenotype relationship between the underlying MEN 1 gene mutation and clinical expression of 
disease.5, 30-32 Genotypically heterogeneous cohorts have also demonstrated an age-related 
penetrance and spectrum of endocrinopathies comparable to the Tasman 1 kindred.3, 5, 31, 33  For 
example, primary hyperparathyroidism is evident in approximately 67% of patients in the Tasman 1 
kindred by 20 years of age and 75% of the genotypically heterogeneous Groupe d'étude des 
Tumeurs Endocrines (GTE) cohort by 21 years of age.5,6, 7 Similarly the prevalence of prolactinoma at 
20 years of age is 20% in the Tasman 1 kindred compared to 24% at 21 years of age in the GTE 
cohort.6, 7, 33 Thus, while we cannot exclude the possibility that other MEN 1 genotypes may 
differentially impact reproductive success, the lack of any reproducible genotype-phenotype 
relationship to date, comparable phenotypic expression and existence of other large MEN 1 kindreds 
in Finland,34 Canada,35 Belgium/France4, 30 and the United States36, 37 among others suggests our 
experience is not uncommon. 
Our study had potential limitations. The impact of potential misclassification was minimised as 
described above. The impact of evaluating a single genotype on the generalisability of our findings 
has also been discussed. Our historical data demonstrate that the reproductive success of a subset 
of MEN 1+ individuals may have been impacted by MEN 1-related pathology, however provided 
insufficient resolution to aid in predicting which individuals are particularly at risk. Similarly, 
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pregnancy complications that did not result in miscarriage or fetal demise were below the resolution 
of this historical database. Nonetheless, the absence of an era-dependent deficit in births suggests 
that the majority of MEN 1-associated pregnancies can proceed without events of sufficient 
magnitude to compromise the pregnancy.  
  
In conclusion, there was no adverse impact of MEN 1 on patient fertility overall, however MEN 1-
related pathology may have impaired the reproductive potential of a subset of individuals with 
pituitary disease. For the majority of MEN 1-related pregnancies, judicious investigation with a 
tendency towards careful antenatal observation appears to be a reasonable approach. Targeted 
intervention should be reserved for selected individuals with high risk phenotypes.  
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Table 1. Cohort characteristics and fertility outcomes stratified by parental MEN1 status 
 
 
Parental MEN 1 status 
 
 
p value 
  
 
MEN 1+ 
 (n=63) 
 
MEN 1- 
 (n=75) 
    
Parental year of birth* 1929 (22.3) 1929 (24.5) 0.93 
Parental gender (% fathers) 42.8 56.0 0.12 
    
Average births (total) 4.9 (4.1) 3.7 (3.3) 0.06 
   Sons  2.3 (2.3) 2.0 (1.9) 0.37 
   Daughters  2.5 (2.3) 1.7 (1.8) 0.02 
    
Live births  4.8 (4.1) 3.6 (3.3) 0.06 
Stillborn children, % of total 
births 
1.0 1.1 0.75 
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Paternal births 5.3 (4.7) 3.7 (3.3) 0.12 
Maternal births 4.4 (3.5) 3.7 (3.3) 0.40 
    
Average births per era    
  Parent born ≤1929 6.32 (4.98) 4.21 (4.12) 0.07 
  Parent born >1929 3.22 (1.96) 3.08 (1.99) 0.76 
    
Total births    
  <20yoa 23 15  
  20-25yoa 81 74  
  25-30yoa 81 81  
  30-35yoa 58 57  
  >35yoa 46 38 0.78 
    
Interference with reproductive 
lifespan† (%) 
14.3 8 0.24 
    
Boldface denotes statistically significant result. 
Mean (SD), except for percentages. p values determined by t-test or χ2 tests as appropriate. 
*Median year of birth and interquartile range 
†Interference with reproductive lifespan was defined as death or significant pathology that was 
highly likely to have impacted fertility between 16-44 years.
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Table 2. Events or pathology interfering with reproductive lifespan (16-44 years) stratified 
by MEN 1 status   
 
 
Pathology or event 
 
Number of kindred members  
 
 
 
MEN 1+  
 
MEN 1- 
Clinically overt pituitary pathology 2 0 
Death secondary to malignancy  5 0 
Death secondary to complications of hypercalcemia  1 0 
Death secondary to accident 1 2 
Death secondary to ischemic heart disease 0 3 
Death secondary to infection 0 1 
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Table 3. Multivariate fertility outcomes of MEN 1+ kindred members referenced against 
MEN 1- kindred members 
 Model 1†  
RR (95% CI) 
Model 2‡  
RR (95% CI) 
 Number of births  1.28 (1.00-1.64) 1.30 (1.02-1.66) 
 Number of sons 1.14 (0.85-1.54) 1.16 (0.86-1.55) 
 Number of daughters 1.44 (1.07-1.93) 1.46 (1.09-1.95) 
 Number of paternal births 1.42 (1.02-1.99) 1.45 (1.03-2.05) 
 Number of maternal births 1.16 (0.81-1.65) 1.14 (0.80-1.61) 
  Live births 1.30 (1.01-1.66) 1.31 (1.02-1.67) 
  Stillborn children 1.24 (0.24-6.36) 1.24 (0.24-6.36) 
Boldface denotes statistically significant result. 
†Model 1: adjusted for parental date of birth and gender.  
‡Model 2: adjusted for parental date of birth, gender and interference with reproductive lifespan 
(16-44 years of age) due to death or significant pathology likely to interfere with reproductive 
potential. 
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Table 4. Pregnancy outcomes for MEN 1+ parents stratified by parent gender 
 
 
MEN 1+ parent 
 
 
p value 
  
 
Father 
 (n=27) 
 
Mother  
 (n=35) 
Parental year of birth* 1928 (16.8) 1930 (25.5) 0.96 
    
Average births (total) 5.3 (4.7) 4.4 (3.5) 0.40 
   Sons  2.3 (2.4) 2.2 (1.8) 0.80 
   Daughters  2.7 (1.9) 2.2 (2.2) 0.36 
    
Live births  5.3 (4.7) 4.3 (3.5) 0.35 
Stillborn children, % of total 
births 
0.6 1.3 0.52 
    
MEN 1+ births 2.2 (1.9) 1.9 (1.9) 0.56 
  MEN 1+ sons 19 28  
  MEN 1+ daughters 38 35 0.21 
    
MEN 1- births 2.7 (2.6) 2.2 (2.1) 0.42 
  MEN 1- sons 39 40  
  MEN 1- daughters 29 33 0.76 
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Average births per era    
  Parent born ≤1929 7.54 (5.80) 5.38 (4.51) 0.28 
  Parent born >1929 3.21 (1.72) 3.53 (2.24) 0.65 
    
Total births    
  <20yoa 4 19  
  20-25yoa 29 52  
  25-30yoa 44 37  
  30-35yoa 28 30  
  >35yoa 33 13 <0.001 
    
Boldface denotes statistically significant result. 
Mean (SD), except for percentages. p values determined by t-test or χ2 tests as appropriate. 
*Median year of birth and interquartile range 
 
 
